1/13, 11:25 PM (Source: TeleTrader)
more TeleTrader news

J&J's one-dose COVID vaccine safe in early trials

Interim analysis of the one-shot coronavirus vaccine developed by Johnson & Johnson proved the candidate to be safe while also providing a promising immune response, data published on Wednesday in the New England Journal of Medicine showed.

In Phase 1 and Phase 2 studies, 57 days after the vaccination, all trial participants between the ages of 18 and 55 produced detectable levels of neutralizing antibodies and remained stable for at least 71 days, the data showed. Phase 3 trial results, however, are expected later in January.

Johnson & Johnson shares ended the day at $157.89 and were up 1.24% in after-hours trade following the publication, going for $159.85 per share.

Breaking the News / NL